drugset / Trial / NCT02750358
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Phase 2
Active not recruiting
50 enrolled
Memorial Sloan Kettering Cancer Center
Astellas Pharma Inc · collabMedivation, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial is designed to determine the feasibility of 1 year of adjuvant enzalutamide, an androgen receptor (AR) antagonist for the treatment of patients with early stage, AR(+) triple negative breast cancer (TNBC).
Timeline
- Start
- 2016-05-19
- Primary completion
- 2027-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |